Serum Interleukin-38 and Tumor-Infiltrating Lymphocytes in Primary Brain Tumors

Serum Interleukin-38 and Tumor-Infiltrating Lymphocytes in Primary Brain Tumors

Tumor-infiltrating lymphocytes (TILs) and brain stromal cells produce immunosuppressive cytokines, contributing to an immunosuppressive tumor microenvironment (TME). Interleukin-38 (IL-38) is a novel anti-inflammatory cytokine and a natural modulator of the innate and adaptive immune system. However...

Full description

Saved in:
Bibliographic Details
Published in:Iranian journal of immunology Vol. 21; no. 1; pp. 65 - 73
Main Authors: Haghshenas, Mohammad Reza, Khademolhosseini, Aida, Dehghanian, Amir Reza, Ghanipour, Fereshteh, Ghaderi, Hamid, Khansalar, Soolmaz, Sotoodeh Jahromi, Abdolreza
Format: Journal Article
Language:English
Published: Iran Shiraz Institute for Cancer Research 12-03-2024
Subjects:
Brain cancer
Brain tumors
Cytokines
Enzyme-linked immunosorbent assay
Immune system
Inflammation
Lymphocytes
Serum levels
Statistical analysis
Stromal cells
Tumor microenvironment
Tumor-infiltrating lymphocytes
Tumors
Tumor-Infiltrating Lymphocytes
Interleukin-38
Brain Tumors
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Tumor-infiltrating lymphocytes (TILs) and brain stromal cells produce immunosuppressive cytokines, contributing to an immunosuppressive tumor microenvironment (TME). Interleukin-38 (IL-38) is a novel anti-inflammatory cytokine and a natural modulator of the innate and adaptive immune system. However, its biological roles in brain tumors are not well defined. To assess the serum levels of IL-38 and the percentages of TILs in the tumor tissues of patients with primary brain tumors and to determine their associations with the pathological features of the disease. IL-38 was evaluated in sera using the enzyme-linked immunosorbent assay (ELISA). Hematoxylin and eosin (H&E)-stained sections were scored to determine the percentages of TILs in four different areas: the invasive margin, central tumor, perivascular and perinecrotic areas. IL-38 serum levels were significantly higher in low- and high-grade tumors than in healthy individuals, meanwhile, its levels remained consistent between these two grades. Although no significant difference was found in IL-38 serum levels between different histological subtypes of brain tumors, its levels were significantly higher in intra-axial brain tumors than in extra-axial ones. Additionally, a significant positive correlation was observed between serum levels of IL-38 and tumor size in patients with low-grade tumors. TILs were detected in at least one of the four examined areas; however, no statistically significant correlation was found between IL-38 levels and TILs. Our data may suggest a connection between IL-38 and immune suppression and tumor progression in primary brain tumors. Further investigation is needed to uncover the role of IL-38 in the brain tumor microenvironment.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1735-1383
1735-367X
DOI:10.22034/iji.2024.100597.2697